Decibel Therapeutics Stock Current Ratio
Decibel Therapeutics fundamentals help investors to digest information that contributes to Decibel Therapeutics' financial success or failures. It also enables traders to predict the movement of Decibel Stock. The fundamental analysis module provides a way to measure Decibel Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Decibel Therapeutics stock.
Decibel |
Decibel Therapeutics Company Current Ratio Analysis
Decibel Therapeutics' Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current Decibel Therapeutics Current Ratio | 6.18 X |
Most of Decibel Therapeutics' fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Decibel Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
CompetitionIn accordance with the recently published financial statements, Decibel Therapeutics has a Current Ratio of 6.18 times. This is 112.37% higher than that of the Biotechnology sector and 11.71% lower than that of the Health Care industry. The current ratio for all United States stocks is 186.11% lower than that of the firm.
Decibel Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Decibel Therapeutics' direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Decibel Therapeutics could also be used in its relative valuation, which is a method of valuing Decibel Therapeutics by comparing valuation metrics of similar companies.Decibel Therapeutics is currently under evaluation in current ratio category among its peers.
Decibel Fundamentals
| Return On Equity | -0.77 | |||
| Return On Asset | -0.33 | |||
| Current Valuation | 62.95 M | |||
| Shares Outstanding | 25.13 M | |||
| Shares Owned By Insiders | 13.35 % | |||
| Shares Owned By Institutions | 61.90 % | |||
| Number Of Shares Shorted | 78.33 K | |||
| Price To Book | 0.67 X | |||
| EBITDA | (62.49 M) | |||
| Net Income | (63.01 M) | |||
| Cash And Equivalents | 125.65 M | |||
| Cash Per Share | 5.03 X | |||
| Total Debt | 14.05 M | |||
| Debt To Equity | 0.14 % | |||
| Current Ratio | 6.18 X | |||
| Book Value Per Share | 2.12 X | |||
| Cash Flow From Operations | (56.9 M) | |||
| Short Ratio | 0.60 X | |||
| Earnings Per Share | (2.56) X | |||
| Target Price | 7.63 | |||
| Number Of Employees | 68 | |||
| Beta | -0.21 | |||
| Market Capitalization | 127.14 M | |||
| Total Asset | 123.37 M | |||
| Retained Earnings | (277.52 M) | |||
| Working Capital | 85.59 M | |||
| Z Score | 1.44 | |||
| Net Asset | 123.37 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Other Consideration for investing in Decibel Stock
If you are still planning to invest in Decibel Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Decibel Therapeutics' history and understand the potential risks before investing.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |